Incyte CorporationINCY

NASDAQHealthcareBiotechnology$92.54+0.55%

A biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics, primarily in oncology. Investors track Incyte for its flagship product Jakafi (ruxolitinib) and pipeline of novel cancer treatments targeting JAK and other pathways.

Market Cap: $18.4B52W Range: $53.56 – $112.29

Congressional Interest in Incyte Corporation (INCY)

9 members of Congress have disclosed 25 trades in Incyte Corporation (INCY), a Healthcare company. The buy/sell breakdown shows 13 purchases versus 12 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.